Fate Therapeutics (FATE) vs Zentalis Pharmaceuticals (ZNTL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Zentalis Pharmaceuticals (ZNTL) has outperformed Fate Therapeutics (FATE) over the past year, gaining 53.0% versus a gain of 41.1%. Over five years, FATE leads with a -96.5% price change compared with -96.6% for ZNTL. Fate Therapeutics is the larger company by market cap ($261.2 million vs $259.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | FATE | ZNTL |
|---|---|---|
| Share price | $2.18 | $2.64 |
| Market cap | $261.21M | $259.04M |
| 1-day change | +2.35% | +5.18% |
| YTD return | +117.35% | +85.93% |
| 1-year return | +41.06% | +53.05% |
| 5-year return | -96.52% | -96.65% |
| EPS (TTM) | $-1.05 | $-1.96 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.23 | $6.95 |
| 52-week low | $0.95 | $1.21 |
| Distance from 52-week high | -32.51% | -62.01% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +163.30% | +177.65% |
| Average volume | 1.86M | 1.21M |
| Shares outstanding | 119.82M | 98.12M |
| Employees | 161 | 106 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ZNTL has outperformed FATE by 12.0 percentage points over the past year.
About Fate Therapeutics
FATE stock →Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 161 employees
About Zentalis Pharmaceuticals
ZNTL stock →Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. It develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types.
Health Care · Biotechnology: Pharmaceutical Preparations · 106 employees
FATE vs ZNTL FAQ
Which is bigger, Fate Therapeutics or Zentalis Pharmaceuticals?
Fate Therapeutics (FATE) is larger, with a market capitalization of $261.21M compared with $259.04M for Zentalis Pharmaceuticals (ZNTL).
Which stock has performed better over the past year, FATE or ZNTL?
ZNTL returned +53.05% over the past 12 months, compared with +41.06% for FATE (price return, excluding dividends). Past performance does not predict future results.
Are Fate Therapeutics and Zentalis Pharmaceuticals in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Fate Therapeutics and Biotechnology: Pharmaceutical Preparations for Zentalis Pharmaceuticals.